Gilead Subsidiary to Launch Generic HCV Drugs

By Marie Rosenthal

Gilead Sciences Inc. plans to launch authorized generic versions of Epclusa (sofosbuvir-velpatasvir) and Harvoni (ledipasvir-sofosbuvir), the company’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. 

The authorized generics will launch at a list price of $24,000 for the most common course of therapy and will be available in January 2019.

Since the launch of Gilead’s first